Other Mutations: MAGE-A1/3/4/6

NCT05129280: A Study to Evaluate Safety, Pharmacokinetics, and Preliminary Anti-tumor Activity of RO7444973 in Participants With Unresectable and/or Metastatic MAGE-A4-positive Solid Tumors

NCT05129280
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: MAGE-A1/3/4/6, HLA+
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1
Drug Category: Immunotherapy, Therapeutic Antibody

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Patients must have tumors that express HLA-A*02:01 AND MAGE-A4
Exclusions: Patients with a history or clinical evidence of central nervous system (CNS) metastases
https://ClinicalTrials.gov/show/NCT05129280

NCT04639245: Genetically Engineered Cells (MAGE-A1-specific T Cell Receptor-transduced Autologous T-cells) and Atezolizumab for the Treatment of Metastatic Triple Negative Breast Cancer, Urothelial Cancer, or Non-small Cell Lung Cancer

NCT04639245
Breast Cancer Type: Triple Negative
Hormone Mutations:
Other Mutations: MAGE-A1/3/4/6, HLA+
Breast Cancer Tissue: 
Recruitment Status: Suspended
Phase 1|Phase 2
Drug Category: Therapeutic Antibody, Immunotherapy, Chemotherapy

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Patients who have been previously treated with a PD-1 or PD-L1 inhibitor (e.g. pembrolizumab, nivolumab, avelumab, atezolizumab, durvalumab) & must have also developed progression or still have detectable disease; Patients must have tumors that express HLA-A*02:01
Exclusions: Patients with tumors that express HLA B*4901; Patients with uncontrolled unstable symptomatic brain metastasis- see trial for details
https://ClinicalTrials.gov/show/NCT04639245

Up ↑